Literature DB >> 3950449

Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production.

M K Hostetter.   

Abstract

To assess serotypic variability in resistance to phagocytosis and in elicitation of antibody response among virulent pneumococci, we quantitated covalently bound C3b and analyzed the C3b degradation fragments for log-phase pneumococci of serotypes 3, 4, 6A, and 14 after opsonization for 20 and 90 min. In C3/C4-deficient agammaglobulinemic serum reconstituted with [3H]C3, covalent binding ranged from 2.9 X 10(4) to 1.5 X 10(5) C3b molecules per organism and increased at least two-fold in the presence of type-specific anticapsular antibody. We compared amide- and ester-linked forms of covalently bound C3b among unencapsulated and encapsulated isolates and differentiated cell wall from capsular binding. Analysis of proteolytic degradation of C3b, covalently bound at the capsular level, revealed C3b, iC3b, and C3d on the capsular surfaces of serotypes 3 and 4, whereas serotypes 6A and 14 displayed only iC3b. We conclude that pneumococcal serotypes, differing in their capsular polysaccharide, differ as well in the amount and site of covalently bound C3b and in its degradative processing to iC3b and C3d. We describe how these differences may explain the well-recognized patterns of serotypic variance in resistance to phagocytosis and in stimulation of antibody production.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3950449     DOI: 10.1093/infdis/153.4.682

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  61 in total

1.  Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae.

Authors:  Melanie Abeyta; Gail G Hardy; Janet Yother
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

2.  Influence of serotype of group B streptococci on C3 degradation.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1992-11       Impact factor: 3.441

Review 3.  Modifications to the peptidoglycan backbone help bacteria to establish infection.

Authors:  Kimberly M Davis; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2010-11-01       Impact factor: 3.441

4.  Deposition and degradation of C3 on type III group B streptococci.

Authors:  J R Campbell; C J Baker; M S Edwards
Journal:  Infect Immun       Date:  1991-06       Impact factor: 3.441

5.  Impact of the molecular form of immunoglobulin A on functional activity in defense against Streptococcus pneumoniae.

Authors:  Claudine E Fasching; Tracy Grossman; Blaise Corthésy; Andrew G Plaut; Jeffrey N Weiser; Edward N Janoff
Journal:  Infect Immun       Date:  2007-01-29       Impact factor: 3.441

6.  Kinetics and avidity of antibodies evoked by heptavalent pneumococcal conjugate vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial.

Authors:  Nina Ekström; Heidi Ahman; Jouko Verho; Jukka Jokinen; Merja Väkeväinen; Terhi Kilpi; Helena Käyhty
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

7.  Resistance to both complement activation and phagocytosis in type 3 pneumococci is mediated by the binding of complement regulatory protein factor H.

Authors:  C Neeleman; S P Geelen; P C Aerts; M R Daha; T E Mollnes; J J Roord; G Posthuma; H van Dijk; A Fleer
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

Review 8.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

9.  Deposition of complement components on Streptococcus agalactiae in bovine milk in the absence of inflammation.

Authors:  P Rainard; B Poutrel
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  An association between homozygous C3 deficiency and low levels of anti-pneumococcal capsular polysaccharide antibodies.

Authors:  M A Hazlewood; D S Kumararatne; A D Webster; M Goodall; P Bird; M Daha
Journal:  Clin Exp Immunol       Date:  1992-03       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.